Graviti Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Graviti Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $101.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Graviti Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $101.1M Trade | TransData Nexus

Graviti Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · CNS & Psychiatric Specialist · $101.1M Total Trade · DGFT Verified

Graviti Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $101.1M across 6 products in 4 therapeutic categories. Based on 4,470 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Gabapentin ($27.0M), Calcium ($25.0M), Atorvastatin ($24.0M).

Graviti Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Graviti Pharmaceuticals Private Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Graviti Pharmaceuticals Private Limited? — Company Overview & Market Position

Graviti Pharmaceuticals Private Limited, established on December 27, 2012, is a privately held pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24232TG2012PTC085058.

As of September 1, 2025, Graviti Pharmaceuticals employed approximately 841 individuals. The company's authorized capital stands at ₹500 crore, with a paid-up capital of ₹490 crore, reflecting a 98% paid-up ratio. Graviti Pharmaceuticals operates with a strong focus on research and development, aiming to provide high-quality, affordable pharmaceutical products globally.

What Does Graviti Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Gabapentin$27.0M 2Calcium$25.0M

Product Portfolio — Top 6 by Export Value

Graviti Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gabapentin	CNS & Psychiatric	$27.0M	849	3.1%	9
2	Calcium	Vitamins & Supplements	$25.0M	713	2.8%	7
3	Atorvastatin	Cardiovascular	$24.0M	664	2.2%	9
4	Furosemide	Diuretics	$14.3M	1,728	20.3%	2
5	Citalopram	CNS & Psychiatric	$5.4M	258	2.1%	11
6	Escitalopram	CNS & Psychiatric	$5.4M	258	2.7%	8

Graviti Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $101.1M. The top category is CNS & Psychiatric (37.4% of portfolio), followed by Vitamins & Supplements (24.7%), indicating a concentrated portfolio with the top 5 products accounting for 94.7% of total export value.

Graviti Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Graviti Pharmaceuticals operates state-of-the-art manufacturing facilities in Hyderabad, Telangana, India. These facilities are equipped to produce a wide range of finished pharmaceutical formulations, including oral solid dosage forms, specialty formulations, and advanced drug delivery systems. The company adheres to stringent manufacturing standards, ensuring compliance with global regulatory requirements.

3Key Leadership

The leadership team at Graviti Pharmaceuticals includes:

Dheeraj Kumar Gorukanti: Managing Director, appointed on December 27, 2012.

Suguna Raman: Director, appointed on December 27, 2012.

Jaganmohan Rao Boinapalli: Additional Director, appointed on March 24, 2025.

Murali Sanyasi Rao Vasireddy Vasudeva: Company Secretary, appointed on October 6, 2019.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Graviti Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Graviti Pharmaceuticals has established a significant presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. The company has received approvals from the U.S. Food and Drug Administration (FDA) and complies with Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO). These certifications enable Graviti Pharmaceuticals to market its products in these regions, ensuring adherence to stringent quality and safety standards.

2Emerging Markets

Graviti Pharmaceuticals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards facilitates access to these regions, allowing it to offer affordable and high-quality pharmaceutical products to a broader patient base.

3Geographic Strategy

Graviti Pharmaceuticals demonstrates a diversified geographic strategy by exporting to multiple regions, including the United States, Europe, the United Kingdom, Australia, Japan, Africa, Latin America, and Southeast Asia. This approach mitigates concentration risk and positions the company to leverage growth opportunities across various markets. The strategic direction focuses on expanding its global footprint while maintaining compliance with international regulatory standards.

Graviti Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Graviti Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, demonstrating its commitment to providing affordable generic medications. Additionally, Graviti Pharmaceuticals has submitted Drug Master Files (DMFs) to the FDA, ensuring transparency and compliance with regulatory requirements. The company's facilities have undergone FDA inspections, with recent audits resulting in zero 483 observations, reflecting a high standard of manufacturing practices.

2WHO & EU GMP

Graviti Pharmaceuticals adheres to Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO) and the European Union (EU). The company's manufacturing facilities are WHO-GMP certified, ensuring that its products meet international quality standards. Graviti Pharmaceuticals is also in the process of obtaining EU GMP certificates, further expanding its market access in Europe.

3CDSCO & Indian Regulatory

Graviti Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Graviti Pharmaceuticals operates in a competitive landscape, with key competitors in overlapping therapeutic categories. The company's top five exported products—Gabapentin, Calcium, Atorvastatin, Furosemide, and Citalopram—are widely produced by various pharmaceutical companies. Graviti Pharmaceuticals holds a 3.1% market share in Gabapentin, 2.8% in Calcium, 2.2% in Atorvastatin, 20.3% in Furosemide, and 2.1% in Citalopram. The company's portfolio concentration, with the top five products accounting for 94.7% of total exports, indicates a focused approach in its product offerings.

2Key Differentiators

Graviti Pharmaceuticals differentiates itself through its commitment to quality, innovation, and affordability. The company invests significantly in research and development, enabling the creation of next-generation therapies and high-impact pharmaceutical solutions. Its adherence to Good Manufacturing Practices (GMP) and Quality by Design (QbD) principles ensures product integrity and regulatory compliance at every stage. Graviti Pharmaceuticals' focus on responsible partnerships and a culture of value further strengthens its competitive position in the global pharmaceutical market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Graviti Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Graviti Pharmaceuticals has demonstrated a strong track record in manufacturing and exporting pharmaceutical products. The company's total export value of $101.1 million USD across 4,470 shipments reflects consistent performance in international markets. The top five products—Gabapentin, Calcium, Atorvastatin, Furosemide, and Citalopram—account for a significant portion of the company's export portfolio, indicating a focused and reliable supply chain. Graviti Pharmaceuticals' adherence to global regulatory standards and its commitment to quality further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and product quality:

FDA Registration: Confirm that Graviti Pharmaceuticals' manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure that the company holds Good Manufacturing Practices (GMP) certification from the World Health Organization (WHO).

Frequently Asked Questions — Graviti Pharmaceuticals Private Limited

How many pharmaceutical products does Graviti Pharmaceuticals Private Limited export from India?

Graviti Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Gabapentin ($27.0M), Calcium ($25.0M), Atorvastatin ($24.0M), Furosemide ($14.3M), Citalopram ($5.4M). Total export value is $101.1M.

What is Graviti Pharmaceuticals Private Limited's total pharmaceutical export value?

Graviti Pharmaceuticals Private Limited's total pharmaceutical export value is $101.1M, based on 4,470 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Graviti Pharmaceuticals Private Limited cover?

Graviti Pharmaceuticals Private Limited exports across 4 therapeutic categories. The largest are CNS & Psychiatric (37.4%, 3 products), Vitamins & Supplements (24.7%, 1 products), Cardiovascular (23.7%, 1 products).

Get Full Graviti Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.